Ausgabe 4/2017
Inhalt (18 Artikel)
Etiology and complications of thrombocytopenia in hospitalized medical patients
Eric M. Fountain, Gowthami M. Arepally
Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system
Kevin P. Bliden, Rahul Chaudhary, Nafees Mohammed, Adina A. Muresan, Carlos G. Lopez-Espina, Eli Cohen, Gabriel Raviv, Marc Doubleday, Fowzia Zaman, Blessy Mathew, Udaya S. Tantry, Paul A. Gurbel
Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery
Sean van Diepen, Peter D. Merrill, Michel Carrier, Jean-Claude Tardif, Mihai Podgoreanu, John H. Alexander, Renato D. Lopes
Implications of an inpatient warfarin dosing nomogram on safety outcomes post-discharge
Nibal Chamoun, C. Gabriela Macías, Jennifer L. Donovan, Robert Klugman, Joel Gore, Pascale Salameh, Maichi T. Tran
Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease
Denise Kelley, Lauren Thornton Jones, Jun Wu, Nicole Bohm
Family history of venous thromboembolism and mortality after venous thromboembolism: a Swedish population-based cohort study
Bengt Zöller, Mirnabi Pirouzifard, Jan Sundquist, Kristina Sundquist
Evaluation of safety and effectiveness of standardized antifactor Xa-based unfractionated heparin protocols in obese versus non-obese patients
Manuel Isherwood, Michelle L. Murphy, Angela L. Bingham, Laura A. Siemianowski, Krystal Hunter, James M. Hollands
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™
Martin Feuring, Sam Schulman, Henry Eriksson, Ajay J. Kakkar, Sebastian Schellong, Stefan Hantel, Elke Schueler, Jörg Kreuzer, Samuel Z. Goldhaber
Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation
B. Steppich, F. Dobler, L. C. Brendel, G. Hessling, S. L. Braun, A. L. Steinsiek, I. Deisenhofer, A. Hyseni, M. Roest, I. Ott
Prospective evaluation of a bivalirudin to warfarin transition nomogram
Benjamin Hohlfelder, Katelyn W. Sylvester, Jessica Rimsans, David DeiCicchi, Jean M. Connors
Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment
Emmeline Tran, Ashley Duckett, Sarah Fisher, Nicole Bohm
Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study
Simon Mantha, Yimei Miao, Jonathan Wills, Rekha Parameswaran, Gerald A. Soff
Oral antiplatelet drugs in patients with chronic kidney disease (CKD): a review
Homam Ibrahim, Sunil V. Rao
Intravenous thrombolysis for stroke after Dabigatran reversal with Idarucizumab: an update
Manuel Cappellari, Stefano Forlivesi, Giovanna Maddalena Squintani, Roberto Facchinetti, Paolo Bovi
Decompressive surgery in malignant cerebral venous sinus thrombosis: what predicts its outcome?
Rohan Mahale, Anish Mehta, Ravi Gopal Varma, Alangar S. Hegde, Purushottam T. Acharya, Rangasetty Srinivasa
Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy: findings from a “real-world” study
Zhu Zhang, Zhenguo Zhai, Yuanhua Yang, Jun Wan, Wanmu Xie, Jianguo Zhu, Ying H. Shen, Chen Wang
Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial
Alma Rut Oskarsdóttir, Brynja R. Gudmundsdottir, Olafur S. Indridason, Sigrun H. Lund, David O. Arnar, Einar S. Bjornsson, Magnus K. Magnusson, Hulda M. Jensdottir, Brynjar Vidarsson, Charles W. Francis, Pall T. Onundarson
Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement
Tuukka A. Helin, Lauri Virtanen, Mikko Manninen, Jarkko Leskinen, Juhana Leppilahti, Lotta Joutsi-Korhonen, Riitta Lassila